An Open-Label, Non-Comparative Expanded Access Study of the Raf-Kinase Inhibitor Sorafenib (Bay 43-9006) as a Subsequent to First-Line Therapy in Patients with Advanced Renal Cell Carcinoma, Assessing Safety and Efficacy.
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms AUS1
- 08 Jun 2016 Status changed from recruiting to completed.
- 30 Aug 2011 New trial record